A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.
Stracke H, Lindemann A, Federlin K.

Third Medical Department, 
University of Giessen, Germany.
Exp Clin Endocrinol Diabetes. 1996;104(4):311-6. 

Abstract

In a double-blind, randomized, controlled study, the effectiveness of treatment with a combination of Benfotiamine (a lipid-soluble derivative of vitamin B1 with high bioavailability) plus vitamin B6,B12 on objective parameters of neuropathy was studied over a period of 12 weeks on 24 diabetic patients with diabetic polyneuropathy. The results showed a significant improvement (p = 0.006) of nerve conduction velocity in the peroneal nerve and a statistical trend toward improvement of the vibration perception threshold.  Long-term observation of 9 patients with verum over a period of 9 months support the results. Therapy-specific adverse effects were not seen. The results of this double-blind investigation, of the long-term observation and of the reports in the literature support the contention that the neurotropic benfotiamine-vitamin B combination represents a starting point in the treatment of diabetic polyneuropathy.

  | Home |  to order  |
 

  1.   Benfotiamine  prevents diabetic side effects
  2.   Benfotiamine  a new approach to preventing diabetic retinopathy
  3.   Benfotiamine  delays formation of advanced glycosylation end-products
  4.   Benfotiamine  effectiveness in diabetic neuropathy 
  5.   Benfotiamine  efficacy in diabetic polyneuropathy 
  6.   Benfotiamine  efficacy in patients diabetic neuropathy
  7.   Benfotiamine  bioavailability 
  8.   Benfotiamine  treatment of diabetic polyneuropathy 
  9.   Benfotiamine  is indicated in end-stage renal disease 
10.   Benfotiamine  may prevent diabetic complications
11.   Benfotiamine  inhibits formation of advanced glycation end products
12.   Benfotiamine  suppressed the formation of advanced glycation end products

 

 

 

Hit Counter